1-新戊基哌嗪 | 57184-50-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 哌嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-新戊基哌嗪
• 英文名称: 1-(2,2-dimethyl-propyl)-piperazine
• 英文别名: 1-neopentylpiperazine；N-(neopentyl)-piperazine；1-(2,2-Dimethylpropyl)piperazine
• CAS: 57184-50-6
• 化学式: C₉H₂₀N₂
• 分子量: 156.271
• InChiKey: QRHQUUUKPRHWRO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  1-新戊基哌嗪 在 palladium 10% on activated carbon 、 氢气 、 三乙胺 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 62.0h， 生成 4-methyl-2-(4-neopentylpiperazin-1-yl)quinazolin-6-amine
  参考文献：
  名称：

  黑色素浓缩激素受体 1 (MCHR1) 拮抗剂喹唑啉衍生物的设计和优化

  摘要：

  黑色素浓缩激素（MCH）是能量稳态的重要介质，在代谢和中枢神经系统疾病中发挥作用。描述了作为 MCHR1 拮抗剂的新型喹唑啉衍生物的模型支持设计、合成和多参数优化（生物活性、溶解度、代谢稳定性、hERG）。举例说明了该系列先导化合物减肥原理的体内证明。开发了源自​​ β2-肾上腺素能受体 X 射线结构（包括细胞外环）的精制 hMCHR1 同源模型簇，并用于指导设计。

  DOI：

  10.1016/j.bmcl.2012.03.050
• 作为产物：
  描述：

  tert-butyl 4-neopentylpiperazine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 以60%的产率得到1-新戊基哌嗪
  参考文献：
  名称：

  Novel Vanilloid Receptor-1 Antagonists:  3. The Identification of a Second-Generation Clinical Candidate with Improved Physicochemical and Pharmacokinetic Properties

  摘要：

  Based on the previously reported clinical candidate, AMG 517 (compound 1), a series of related piperazinylpyrimidine analogues were synthesized and evaluated as antagonists of the vanilloid 1 receptor (VR1 or TRPV1). Optimization of in vitro potency and physicochemical and pharmacokinetic properties led to the discovery of (R)-N-(4-(6-(4-(1-(4-fluorophenyl)ethyl)piperazin-1-yl)pyrimidin-4-yloxy)benzo[d]thiazol-2-yl)acetamide (16p), a potent TRPV1 antagonist [rTRPV1(CAP) IC50 = 3.7 nM] with excellent aqueous solubility (>= 200 mu g/mL in 0.01 N HCl) and a reduced half-life (rat t(1/2) = 3.8 h, dog t(1/2) = 2.7 h, monkey t(1/2) = 3.2 h) as compared to AMG 517. In addition, compound 16p was shown to be efficacious at blocking a TRPV1-mediated physiological response in vivo (ED50 = 1.9 mg/kg, p.o. in the capsaicin-induced flinch model in rats) and was also effective at reducing thermal hyperalgesia induced by complete Freund's adjuvant in rats (MED = 1 mg/kg, p.o). Based on its improved overall profile, compound 16p (AMG 628) was selected as a second-generation candidate for further evaluation in human clinical trials as a potential new treatment for chronic pain.

  DOI：

  10.1021/jm070191h

文献信息

• HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：Ren Pingda

  公开号：US20120122838A1

  公开（公告）日：2012-05-17

  Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

  调节激酶活性的化合物和药物组合物，包括PI3激酶活性，以及与激酶活性相关的疾病和病况的化合物、药物组合物和治疗方法在此进行描述。
• 11-(Piperazino-acetyl)-5,11-di
  申请人：Boehringer Ingelheim GmbH

  公开号：US04213984A1

  公开（公告）日：1980-07-22

  Compounds of the formula ##STR1## wherein R.sub.1 is alkyl of 3 to 12 carbon atoms; unsaturated aliphatic hydrocarbyl of 3 to 20 carbon atoms comprising 1 to 3 double bonds and/or one triple bond; phenyl(alkyl of 2 to 4 carbon atoms); methylenedioxybenzyl; chlorobenzyl; indan-5-ylmethyl; indan-3-ylmethyl; phenyl(alkenyl of 2 to 4 carbon atoms); cycloalkyl of 5 to 7 carbon atoms; (cycloalkyl of 3 to 10 carbon atoms)methyl; (methylcycloalkyl of 4 to 11 carbon atoms)methyl; morpholino(alkyl of 2 to 3 carbon atoms); pyrrolidino(alkyl of 2 to 3 carbon atoms); piperidino (alkyl of 2 to 3 carbon atoms); 4-methylpiperazino(alkyl of 2 to 3 carbon atoms); or, when R.sub.3 and/or R.sub.4 are methyl or ethyl, also methyl or ethyl; R.sub.2 is hydrogen, methyl or ethyl; and R.sub.3 and R.sub.4 are each hydrogen, methyl or ethyl; and non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds as well as the salts are useful as anti-ulcerogenics and secretion inhibitors.

  式为##STR1##的化合物，其中R.sub.1是3到12个碳原子的烷基；不饱和脂肪烃基，碳原子数为3到20，包括1到3个双键和/或一个三键；苯基（2到4个碳原子的烷基）；亚甲二氧基苯甲基；氯苯甲基；茚-5-基甲基；茚-3-基甲基；苯基（2到4个碳原子的烯基）；5到7个碳原子的环烷基；（3到10个碳原子的环烷基）甲基；（4到11个碳原子的甲基环烷基）甲基；吗啉（2到3个碳原子的烷基）；吡咯啉（2到3个碳原子的烷基）；哌啶（2到3个碳原子的烷基）；4-甲基哌嗪（2到3个碳原子的烷基）；或者，当R.sub.3和/或R.sub.4是甲基或乙基时，也可以是甲基或乙基；R.sub.2是氢、甲基或乙基；R.sub.3和R.sub.4分别是氢、甲基或乙基；以及其非毒性、药理学上可接受的酸盐。这些化合物以及盐可用作抗溃疡剂和分泌抑制剂。
• PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL DISEASES
  申请人：JANSSEN R&D IRELAND

  公开号：US20150087651A1

  公开（公告）日：2015-03-26

  The present invention relates to novel compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein the integers are as defined in the description. The claimed compounds are useful for the treatment of a bacterial infection. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of a bacterial infection and a process for preparing the claimed compounds.

  本发明涉及以下式I的新化合物： 或其药学上可接受的盐，其中整数如描述中所定义。 所述化合物可用于治疗细菌感染。还声明了一种包含药学上可接受的载体和所述化合物的治疗有效量作为活性成分的组合物，所述化合物或组合物用于制造治疗细菌感染药物的声明以及制备所述化合物的方法。
• NEW COMPOUNDS
  申请人：PROXIMAGEN LIMITED

  公开号：US20160024080A1

  公开（公告）日：2016-01-28

  The compound of formula (I) are inhibitors of SSAO activity (Formula (I)) wherein the terms Y, Z, W, R 1 and R 2 are defined in the claims.

  化合物的化学式（I）是SSAO活性的抑制剂（化学式（I）），其中术语Y、Z、W、R1和R2在专利权要求中有定义。
• SERINE/THREONINE KINASE INHIBITORS
  申请人：Genentech, Inc.

  公开号：US20140323477A1

  公开（公告）日：2014-10-30

  Compounds having the formula I, or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , X 1 , X 2 , and Ar are as defined herein, are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders using such compounds.

  具有公式I或其药用可接受的盐的化合物，其中R1、R2、X1、X2和Ar如本文所定义，是PAK1的抑制剂。还公开了使用这些化合物治疗癌症和增生性疾病的组合物和方法。